Seattle Genetics, Astellas’ bladder cancer med Padcev blows early expectations out of the water

Seattle-based Seattle Genetics and Astellas’ new bladder cancer treatment, Pandcev exceeded sales expectations in Q1. 

In a note to clients, J.P. Morgan analyst, Cory Kasimov wrote: “blew out expectations … exceeding consensus estimates.”

READ THE ARTICLE at FiercePharma »

PHOTO: Seattle Genetics’ Padcev picked up its first approval in mid-December, 2019. (Image courtesy Seattle Genetics)